Inegy

Simvastatin and ezetimibe, the active ingredients in Inegy, are a statin and cholesterol absorption inhibitor presented as an oral tablet for oral use. They are prescribed to lower elevated cholesterol and triglyceride levels in adults with various lipid disorders.

GNH USA supplies Inegy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Inegy is indicated for lipid disorders that involve elevated LDL‑cholesterol and mixed lipid abnormalities. - Hypercholesterolemia: reduces LDL‑cholesterol to target levels. - Mixed dyslipidemia: lowers LDL‑C and triglycerides while modestly increasing HDL‑C. - Primary hyperlipidemia: improves overall lipid profile in patients with elevated cholesterol.

Inegy may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Myalgia or muscle aches: occasional, usually transient. - Abdominal discomfort: includes pain or cramping. - Diarrhea: loose stools occurring shortly after dosing. - Nausea: occasional feeling of queasiness. - Elevated liver enzymes: mild increases in ALT/AST.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with risk of renal failure. - Acute liver injury: marked elevation of hepatic enzymes or jaundice. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Myopathy: significant muscle weakness with CK elevation. - Pancreatitis: abdominal pain with elevated pancreatic enzymes. - Hepatitis: inflammation of the liver presenting with systemic symptoms.

Before initiating therapy, clinicians should evaluate patient history and monitor relevant parameters. - Liver function monitoring: assess baseline ALT/AST and repeat periodically. - Muscle symptom assessment: educate patients to report unexplained muscle pain or weakness. - Avoid use in active liver disease: contraindicated in patients with hepatic impairment. - Pregnancy and lactation review: generally avoided due to limited safety data. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Inegy can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): increase simvastatin exposure. - Gemfibrozil: markedly raises risk of myopathy. - High‑dose niacin: potentiates muscle toxicity. - Cyclosporine: elevates both components' plasma levels. - Protease inhibitors (e.g., ritonavir): significantly increase simvastatin concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, monitor INR. - Digoxin: potential increase in serum levels. - Antacids containing aluminum or magnesium: may affect ezetimibe absorption. - Beta‑blockers: monitor for additive lipid‑lowering effects. - Other fibrates (except gemfibrozil): watch for muscle toxicity. - Amiodarone: may increase risk of hepatic enzyme elevation.